Combination of the biomarkers for aging and cancer? - Challenges and current status
Copyright © 2023. Published by Elsevier Inc..
The proportion of patients diagnosed with cancer has been shown to rise with the increasing aging global population. Advanced age is a major risk factor for morbidity and mortality in older adults. As individuals experience varying health statuses, particularly with age, it poses a challenge for medical professionals in the cancer field to obtain standardized treatment outcomes. Hence, relying solely on chronological age and disease-related parameters is inadequate for clinical decision-making for elderly patients. With functional, multimorbidity-related, and psychosocial changes that occur with aging, oncologic diseases may develop and be treated differently from younger patients, leading to unique challenges in treatment efficacy and tolerance. To overcome this challenge, personalized therapy using biomarkers has emerged as a promising solution. Various categories of biomarkers, including inflammatory, hematological, metabolic, endocrine, and DNA modification-related indicators, may display features related to both cancer and aging, aiding in the development of innovative therapeutic approaches for patients with cancer in old age. Furthermore, physical functional measurements as non-molecular phenotypic biomarkers are being investigated for their potential complementary role in structured multidomain strategies to combat age-related diseases such as cancer. This review provides insight into the current developments, recent discoveries, and significant challenges in cancer and aging biomarkers, with a specific focus on their application in advanced age.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Translational oncology - 38(2023) vom: 15. Dez., Seite 101783 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Dai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aging |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.tranon.2023.101783 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362133514 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362133514 | ||
| 003 | DE-627 | ||
| 005 | 20231226090616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tranon.2023.101783 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362133514 | ||
| 035 | |a (NLM)37716258 | ||
| 035 | |a (PII)S1936-5233(23)00169-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Dai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of the biomarkers for aging and cancer? - Challenges and current status |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a The proportion of patients diagnosed with cancer has been shown to rise with the increasing aging global population. Advanced age is a major risk factor for morbidity and mortality in older adults. As individuals experience varying health statuses, particularly with age, it poses a challenge for medical professionals in the cancer field to obtain standardized treatment outcomes. Hence, relying solely on chronological age and disease-related parameters is inadequate for clinical decision-making for elderly patients. With functional, multimorbidity-related, and psychosocial changes that occur with aging, oncologic diseases may develop and be treated differently from younger patients, leading to unique challenges in treatment efficacy and tolerance. To overcome this challenge, personalized therapy using biomarkers has emerged as a promising solution. Various categories of biomarkers, including inflammatory, hematological, metabolic, endocrine, and DNA modification-related indicators, may display features related to both cancer and aging, aiding in the development of innovative therapeutic approaches for patients with cancer in old age. Furthermore, physical functional measurements as non-molecular phenotypic biomarkers are being investigated for their potential complementary role in structured multidomain strategies to combat age-related diseases such as cancer. This review provides insight into the current developments, recent discoveries, and significant challenges in cancer and aging biomarkers, with a specific focus on their application in advanced age | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aging | |
| 650 | 4 | |a Biological age | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Epigenetic modification | |
| 650 | 4 | |a Frailty | |
| 650 | 4 | |a Geriatric oncology | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Metabolism | |
| 700 | 1 | |a Ju, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Chunfu |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Jule C |e verfasserin |4 aut | |
| 700 | 1 | |a Gul, Sheraz |e verfasserin |4 aut | |
| 700 | 1 | |a Zaliani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Wartmann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Polidori, Maria Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bruns, Christiane J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational oncology |d 2008 |g 38(2023) vom: 15. Dez., Seite 101783 |w (DE-627)NLM180720333 |x 1936-5233 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g day:15 |g month:12 |g pages:101783 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tranon.2023.101783 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |b 15 |c 12 |h 101783 | ||